Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center experience

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2722-2730

  Diamandidou, E ^a   Buzdar, A U ^a   Smith, T L ^a   Frye, D ^a   Witjaksono, M ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029782022     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2722     Document Type: Article

References (37)

1. Fisher B, Redmond C, Welmark N, et al: Breast cancer studies of the NSABP: An editorialized overview, in Jones S, Salmon S (eds): Adjuvant Therapy of Cancer III. New York, NY, Grune & Stratton, 1981, pp 359-370
2. Henderson IC: Adjuvant systemic therapy of early breast cancer, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1987, pp 324-353
3. Consensus Conference: Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985
4. Greene MH, Harris EL, Gershenson DM, et al: Melphalan may be a more potent leukemogen than cyclophosphamide. Ann Intern Med 105:360-367, 1986
5. Curtis R, Boice J, Stovall M, et al: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326:1745-1751, 1992
6. Valagussa P, Tanani G, Bonadonna G: Second malignancies after CMF for resectable breast cancer. J Clin Oncol 5:1138-1142, 1987
7. Valagussa P, Moliterni A, Terenziani M, et al: Second malignancies following CMF- based adjuvant chemotherapy in resectable breast cancer. Ann Oncol 5:803-808, 1994
8. Tallman MS, Gray R, Bennet JM: Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: Eastern Cooperative Oncology Group experience. J Clin Oncol 13:1557-1563, 1995
9. Rossi A, Bonadonna G, Valagussa P, et al: Multimodal treatment in operable breast cancer. 5-year results of the CMF programme. Br Med J 282:1427-1431, 1981
10. Bonadonna G, Valagussa P, Moliterni A, et al: Risk of acute leukemia and other malignancies following CMF-based adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 12:61, 1993 (abstr45)
11. Le Beau MM, Albain KS, Larson RA, et al: Clinical and cytogenetic correlations in 62 patients with therapy-related myelodysplastic syndrome and acute non- lymphocytic leukemia: Further evidence for characteristic abnormalities of chromosome 5 and 7. J Clin Oncol 4:325-345, 1986
12. Kantarjian H, Keating M, Walters R, et al: Treatment related leukemias and myelodysplastic syndrome: Clinical cytogenetics and prognostic features. J Clin Oncol 4:1748-1757, 1986
13. Rowley J, Golomb H, Vardiman J, et al: Nonrandom chromo- some abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 58:759-767, 1981
14. Michels S, McKenna R, Arthur D, et al: Therapy-related acute-myeloid leukemia and myelodysplastic syndrome: A clinical and morphologic study of 65 cases. Blood 65:1364-1372, 1985
15. Pedersen-Bjergaard J, Sigsgaard T, Nielsen D, et al: Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after treatment with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10:1444-1451, 1992
16. Pedersen-Bjergaard J, Philip P, Ravn V, et al: Therapy related acute nonlymphocytic leukemia of FAB type M4 or M5 with early onset and t(9; 11)(p21;q23) or a normal karyotype. A separate entity? J Clin Oncol 6:395, 1988 (letter)
17. Chambers SK, Chopyk RL, Chambers JT, et al: Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer. Cancer 64:2459-2461, 1989
18. Albain KS, LeBeau MM, Ullirsch R, et al: Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy related monocytic leukemia with a 9; 11 translocation. Genes Chromosomes Cancer 2:53-58, 1990
19. Sandoval C, Pui C-H, Raimondi SC, et al: Epipodophyllotoxin related secondary acute myeloid leukemia. Proc Am Soc Clin Oncol 11:279, 1992 (abstr 925)
20. Ratain MJ, Rowley JD: Therapy related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genes. Ann Oncol 3:107-111, 1992
21. Riggi M, Riva A : Therapy related leukemia. What is the role of 4-epi-doxorubicin? J Clin Oncol 11:1430-1435, 1993
22. Sandoval C, Pui C-H, Head D, et al: Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topo-II inhibitors and irradiation. J Clin Oncol 11:1039-1045, 1993
23. Decillis A, Anderson S, Wickerham DL, et al: Acute myeloid leukemia (AML) in NSABP B-25. Proc Am Soc Clin Oncol 14:98, 1995 (abstr 92)
24. Rubin CM, Larson RA, Anastassi J, et al: t-(3;21)(q26;q22): A recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 76:2594-2598, 1990
25. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolong observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39, 1977
26. Levine EG, Bloomfield CD: Secondary myelodysplastic syndromes and leukemia. Clin Haematol 15:1037-1080, 1986
27. Fisher B, Rockette H, Fisher ER, et al: Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiotherapy. The NSABP experience. J Clin Oncol 3:1640-1658, 1985
28. Herring MK, Buzdar AU, Smith TL, et al: Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol 9:269-275, 1986
29. Lerner HJ: Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 62:1135-1138, 1978
30. Holdener EE, Nissen-Meyer R, Bonadonna G, et al: Second malignant neoplasms in operable carcinoma of the breast. Recent Results Cancer Res 96:188-191, 1984
31. Geller RB, Boone LB, Karp JC, et al: Secondary acute-myelocytic leukemia after adjuvant therapy for early stage breast carcinoma. Cancer 64:629-634, 1989
32. Cuzick J, Erskine S, Galton D, et al: A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 55:523-529, 1987
33. Boice JD Jr, Greene MH, Killen JY, et al: Leukemia after adjuvant chemotherapy with semustine - Evidence of dose-response effect. N Engl J Med 314:119-120, 1986
34. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 vs 6 cycles. J Clin Oncol 1:2-10, 1983
35. Pizzolo G, Molino A, Sabbioni R, et al: Acute lymphoblastic leukemia after radiotherapy and adjuvant chemotherapy (CMF) for breast cancer. Acta Haematol 65:128-130, 1981
36. Heyn R, Khan F, Eusign L, et al: Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III. A preliminary report. Med Pediatr Oncol 23:99-106, 1994
37. Tewey KN, Rowe TC, Yang L, et al: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-468, 1984